Chimeric antigen receptor and methods of use thereof
The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.
1. A method of stimulating a T-cell mediated immune response to a cancer cell in a human, the method comprising:
A) administering to the human an effective amount of T lymphocytes, wherein the T lymphocytes are genetically modified to produce a heterodimeric chimeric antigen receptor (CAR) comprising a first polypeptide and a second polypeptide, wherein the first and second polypeptides are two separate polypeptides, wherein:
a) the first polypeptide comprises:
i) an extracellular antigen binding domain specific for an epitope on the cancer cell in the human;
ii) a transmembrane domain; and
iii) a first member of a dimerization pair; and
b) the second polypeptide comprises:
i) a transmembrane domain;
ii) a second member of the dimerization pair; and
iii) an intracellular signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM), wherein the intracellular signaling domain provides signal transduction activity,
wherein the first polypeptide, the second polypeptide or both the first and second polypeptides comprise an intracellular costimulatory polypeptide, and
B) administering to the human an effective amount of a dimerizing agent, wherein the dimerizing agent induces dimerization of the heterodimeric CAR when expressed in the cell membranes of the T lymphocytes, wherein said dimerization provides for stimulation of the T-cell mediated immune response in the presence of the epitope on the cancer cell to which said extracellular antigen binding domain specifically binds.
2. The method of claim 1 , wherein the first polypeptide comprises a hinge region interposed between the extracellular antigen binding domain and the transmembrane domain.
3. The method of claim 2 , wherein the hinge region is an immunoglobulin IgG hinge region or a hinge derived from CD8.
4. The method of claim 1 , wherein the intracellular signaling domain comprising the ITAM is selected from the group consisting of CD3-zeta and ZAP70.
5. The method of claim 1 , wherein the first and second members of the dimerization pair are selected from the group consisting of:
a) FK506 binding protein (FKBP) and FKBP-rapamycin associated protein (FRB);
b) a Gibberellic Acid Insensitive (GAI) protein and a gibberellin receptor (GID1) protein;
c) FKBP and calcineurin catalytic subunit A (CnA);
d) an abscisic acid receptor (PYL) protein and an abscissic acid insensitive (ABI) protein;
e) a cryptochrome 2 (Cry2) protein and a transcription factor bHLH63 (CIB1) protein; and
f) FKBP and cyclophilin.
6. The method of claim 1 , wherein the first and second members of the dimerization pair are selected from the group consisting of:
a) FK506 binding protein (FKBP) and FKBP;
b) gyrase B (GyrB) and GyrB;
c) dihydrofolate reductase (DHFR) and DHFR; and
d) DmrB and DmrB.
7. The method of claim 1 , wherein the first member of the dimerization pair is an FK506 binding protein (FKBP), and wherein the second member of the dimerization pair is a FKBP-rapamycin associated protein (FRB).
8. The method of claim 7 , wherein the FKBP comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:12, and wherein the FRB comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:14.
9. The method of claim 1 , wherein the first member of the dimerization pair is GID1, and wherein the second member of the dimerization pair is GAI.
10. The method of claim 9 , wherein the GID1 polypeptide comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in one of SEQ ID NOs:95-97, and wherein the GAI polypeptide comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:94.
11. The method of claim 1 , wherein the cancer cell is a breast cancer cell, a B cell lymphoma, a Hodgkin lymphoma cell, an ovarian cancer cell, a prostate cancer cell, a mesothelioma, a lung cancer cell, a non-Hodgkin B-cell lymphoma cell, an ovarian cancer cell, a prostate cancer cell, a mesothelioma cell, a melanoma cell, a chronic lymphocytic leukemia cell, an acute lymphocytic leukemia cell, a neuroblastoma cell, a glioma, a glioblastoma, a medulloblastoma, or a colorectal cancer cell.
12. The method of claim 1 , wherein the intracellular costimulatory polypeptide is selected from the group consisting of: 4-1BB, CD28, ICOS, OX-40, BTLA, CD27, CD30, GITR, and HVEM.
13. The method of claim 12 , wherein the 4-1BB polypeptide comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:24.
14. The method of claim 12 , wherein the OX-40 polypeptide comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:65.
15. The method of claim 12 , wherein the CD28 polypeptide comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:63.
16. The method of claim 1 , wherein the first polypeptide comprises a first costimulatory polypeptide comprising an amino acid sequence and the second polypeptide comprises a second costimulatory polypeptide comprising an amino acid sequence that has at least 95% amino acid identity to the amino acid sequence of the first costimulatory polypeptide in the first polypeptide.
17. The method of claim 1 , wherein the intracellular signaling domain comprising the ITAM comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in one of SEQ ID NOs:98-119.
18. The method of claim 1 , further comprising administering to the individual a cancer chemotherapeutic agent, an antibody, or a biological response modifier.
19. The method of claim 1 , wherein the first member and the second member of the dimerization pair are intracellular.
20. The method of claim 1 , wherein the extracellular antigen binding domain comprises an antigen-binding single-chain Fv.